JP2000218140A - Module incorporated with membrane and its production - Google Patents

Module incorporated with membrane and its production

Info

Publication number
JP2000218140A
JP2000218140A JP11336126A JP33612699A JP2000218140A JP 2000218140 A JP2000218140 A JP 2000218140A JP 11336126 A JP11336126 A JP 11336126A JP 33612699 A JP33612699 A JP 33612699A JP 2000218140 A JP2000218140 A JP 2000218140A
Authority
JP
Japan
Prior art keywords
module
organic solvent
membrane
concentration
ppb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP11336126A
Other languages
Japanese (ja)
Other versions
JP4622015B2 (en
Inventor
Masaaki Shimagaki
昌明 島垣
Yoshihiro Aga
善広 英加
Masahiro Kubota
昌裕 久保田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to JP33612699A priority Critical patent/JP4622015B2/en
Publication of JP2000218140A publication Critical patent/JP2000218140A/en
Application granted granted Critical
Publication of JP4622015B2 publication Critical patent/JP4622015B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

PROBLEM TO BE SOLVED: To reduce a residual organic solvent and to obtain a module which does not cause the deterioration of not only membranes in the module but also of a main body by specifying the concentration of the organic solvent in a packing liquid or in water after being preserved with ultrapure water put in the module when no packing liquid is absent. SOLUTION: A module incorporated with separation membranes and others is used in various applications. As regards the membranes, the organic solvent solution of a polymer is adjusted and formed in the shapes of a membrane, a hollow fiber membrane, and others. Since the residual organic solvent of the module is minimized, the concentration of the organic solvent in a packing liquid or in water after being preserved at 80 deg.C for 24 hr with ultrapure water put in the module when the packing liquid is absent is set up at 50 ppb or below, preferably at 30 ppb or below. Only by a process in which the assembled module is irradiated with electron beams preferably in a ratio of 1-5 kGy, the organic solvent in the packing liquid can be decomposed.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、残存有機溶媒の少
ない膜を組み込んだモジュール、詳しくは残存有機溶媒
を少なくし膜やモジュールの劣化を防止した膜を組み込
んだモジュールとそのモジュールの製造法に関するもの
である。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a module incorporating a film having a small amount of residual organic solvent, and more particularly to a module incorporating a film having a reduced amount of residual organic solvent and preventing deterioration of the film and the module, and a method of manufacturing the module. Things.

【0002】[0002]

【従来の技術】従来、人工腎臓等の医療分野あるいは水
処理関係で使用されているモジュールには、分離膜や半
透膜が組み込まれている。このような分離膜や半透膜の
製膜には通常有機溶媒が用いられるが、この製膜時に用
いられている有機溶媒は一般には製膜後、膜からは除去
されにくく、特に高沸点の極性溶媒の場合は高濃度に残
存し、この残存有機溶媒の影響で、膜劣化やモジュール
劣化が起こり、水処理関係あるいは医療用途においてモ
ジュール使用時の安全性の点での影響が懸念されてい
た。特に、医療用途において血液浄化に応用される膜の
場合は、残存有機溶媒を除去するために膜の洗浄を強化
し、常温の水のみならず高温の熱水を用いて洗浄した
り、あるいは高圧蒸気滅菌を施し有機溶媒の残存量の低
減化を進めてきた。しかしながら、これらの方法では、
なお残存有機溶媒量を50ppb以下に抑えることはで
きなかった。
2. Description of the Related Art Conventionally, modules used in the medical field such as artificial kidneys or in water treatment are equipped with a separation membrane or a semipermeable membrane. An organic solvent is usually used for forming such a separation membrane or a semipermeable membrane.However, the organic solvent used in this film formation is generally difficult to be removed from the membrane after the film formation, and particularly has a high boiling point. In the case of a polar solvent, it remains at a high concentration, and due to the effect of the remaining organic solvent, membrane deterioration or module deterioration occurs, and there is a concern about the effect on safety when using the module in water treatment or medical use. . In particular, in the case of membranes used for blood purification in medical applications, the membrane cleaning should be strengthened to remove residual organic solvents, and the membrane should be washed using not only room temperature water but also high temperature hot water, or high pressure. Steam sterilization has been carried out to reduce the residual amount of organic solvents. However, with these methods,
Note that the amount of the residual organic solvent could not be suppressed to 50 ppb or less.

【0003】[0003]

【発明が解決しようとする課題】本発明者らは、上記問
題点を克服すべく残存有機溶媒の分解性に着目し鋭意検
討した結果、本発明に到達した。
DISCLOSURE OF THE INVENTION The present inventors have intensively studied the decomposability of a residual organic solvent in order to overcome the above-mentioned problems, and as a result, have reached the present invention.

【0004】本発明の目的は、残存有機溶媒が少なく、
モジュール内部に組み込まれている膜だけではなく本体
の劣化も起こらない膜を組み込んだモジュールを提供す
ることにある。
[0004] An object of the present invention is to reduce the residual organic solvent,
It is an object of the present invention to provide a module incorporating not only a film incorporated in the module but also a film which does not cause deterioration of the main body.

【0005】また本発明の他の目的は、煩雑な工程を必
要とせず、簡単な工程で効率的に残存有機溶媒を除去で
きる上記モジュールの製造法を提供することにある。
It is another object of the present invention to provide a method for manufacturing the above module, which can efficiently remove the residual organic solvent by a simple process without requiring a complicated process.

【0006】[0006]

【課題を解決するための手段】本発明は、上記目的を達
成せんとするものであって、本発明のモジュールは、膜
を組み込んだモジュールにおいて、充填液中の有機溶媒
濃度もしくは充填液がない場合はモジュール内に超純水
を入れ80℃で24時間保存した後の水中における有機
溶媒濃度が、50ppb以下であることを特徴とするも
のであり、前記の膜としては、例えばポリスルホンやポ
リメチルメタクリレート等からなる分離膜や半透膜が挙
げられる。
SUMMARY OF THE INVENTION The object of the present invention is to achieve the above object. In the module of the present invention, there is provided a module incorporating a membrane. In this case, the organic solvent concentration in water after ultrapure water is put in the module and stored at 80 ° C. for 24 hours is not more than 50 ppb, and the membrane is, for example, polysulfone or polymethyl. Examples include a separation membrane and a semi-permeable membrane made of methacrylate or the like.

【0007】また本発明のモジュールの製造法は、膜を
組み込んだモジュールに電子線を照射して、有機溶媒を
分解せしめることを特徴とするもので、残存する有機溶
媒の濃度が50ppb以下になるまで電子線を照射す
る。この電子線の照射で、高沸点の極性溶媒も速やかに
分解することができる。
The method for producing a module according to the present invention is characterized in that an organic solvent is decomposed by irradiating an electron beam to a module incorporating a membrane, and the concentration of the remaining organic solvent becomes 50 ppb or less. Irradiate electron beam up to. By the irradiation of the electron beam, a polar solvent having a high boiling point can be rapidly decomposed.

【0008】[0008]

【発明の実施の形態】分離膜や半透膜等の膜が組み込ま
れたモジュールは、一般産業用、水処理用および血液処
理用等の様々な用途に使用されている。特に血液処理用
モジュールは、メディカル用途において、血漿交換療法
や人工透析治療、さらには人工肝臓、エンドトキシンフ
ィルター、バイオリアクター等の医療用途および産業用
途等、各種用途に用いることができるが、細胞との相互
作用を伴うために特に安全性に配慮する必要がある。
DESCRIPTION OF THE PREFERRED EMBODIMENTS Modules incorporating membranes such as separation membranes and semi-permeable membranes are used for various purposes such as general industrial use, water treatment and blood treatment. In particular, the blood processing module can be used for various purposes such as plasma exchange therapy and artificial dialysis treatment in medical applications, as well as medical uses and industrial uses such as artificial livers, endotoxin filters, and bioreactors. Special consideration must be given to safety because of the interaction.

【0009】本発明のモジュールに組み込まれる膜は、
膜を構成するポリマーの有機溶媒溶液を調整し、これを
膜状または中空糸膜状等に成形することによって得られ
るが、この際、使用した有機溶媒が製膜した膜中に取り
込まれ残存する。有機溶媒はポリマーの良溶媒であり使
用するポリマーの種類により異なる。
[0009] The membrane incorporated in the module of the present invention comprises:
It is obtained by preparing an organic solvent solution of the polymer constituting the membrane and shaping it into a membrane or a hollow fiber membrane or the like. At this time, the organic solvent used is taken in and remains in the formed membrane. . The organic solvent is a good solvent for the polymer and varies depending on the type of the polymer used.

【0010】本発明で用いられるポリマーとしては、ポ
リスルホンやポリメチルメタクリレート等が挙げられ
る。また、使用される有機溶媒としては、塩化メチレン
(沸点:39.95℃)、クロロホルム(沸点:61.
2℃)、1−メチル−2−ピロリドン(沸点:202
℃)、N,N−ジメチルアセトアミド(沸点:164.
5〜166℃)、テトラヒドロフラン(沸点:65〜6
7℃)、ジメチルスルホキシド(沸点:189℃)等が
挙げられる。
[0010] Examples of the polymer used in the present invention include polysulfone and polymethyl methacrylate. The organic solvent used includes methylene chloride (boiling point: 39.95 ° C.) and chloroform (boiling point: 61.95 ° C.).
2 ° C.), 1-methyl-2-pyrrolidone (boiling point: 202
C), N, N-dimethylacetamide (boiling point: 164.
5-166 ° C), tetrahydrofuran (boiling point: 65-6)
7 ° C.), dimethyl sulfoxide (boiling point: 189 ° C.) and the like.

【0011】本発明において、膜を組み込んだモジュー
ル自体の製造は通常の公知の方法を用いればよく、製膜
後モジュール形態に加工するまでにどのような工程を経
てもかまわない。
In the present invention, the module itself incorporating the membrane may be manufactured by a commonly known method, and any steps may be taken after processing into a module after film formation.

【0012】本発明の特徴の一つは、かかるモジュール
において、残存する有機溶媒をできるだけ少なくするも
のであり、具体的には、充填液中の有機溶媒濃度、もし
くは充填液がない場合はモジュール内に超純水を入れ8
0℃で24時間保存した後の水中の有機溶媒濃度を50
ppb以下、好ましくは30ppb以下とするものであ
る。残存有機溶媒をこのように少なくすることにより、
膜自体の劣化を抑えるとともに、モジュール本体の劣化
をも抑えることができる。
One of the features of the present invention is to reduce the remaining organic solvent in such a module as much as possible. Specifically, the concentration of the organic solvent in the filling solution, or the absence of the filling solution in the module, Put ultrapure water into
After storing at 0 ° C. for 24 hours, the concentration of the organic solvent in water was adjusted to 50.
ppb or less, preferably 30 ppb or less. By reducing the residual organic solvent in this way,
The deterioration of the film itself and the deterioration of the module body can be suppressed.

【0013】本発明においては、驚くべきことに、組み
立てられたモジュールに電子線を照射するだけで、充填
液中の有機溶媒を分解させることができ、これにより残
存有機溶媒によるモジュールの劣化や水処理関係、医療
用途での安全性の問題が生じない上記のモジュールを製
造することができる。
In the present invention, surprisingly, it is possible to decompose the organic solvent in the filling liquid only by irradiating the assembled module with an electron beam. It is possible to manufacture the above-mentioned module which does not cause a safety problem in processing-related and medical applications.

【0014】電子線の照射は、純水・生理食塩水等の充
填液を充填した状態のモジュールおよび中空糸が乾燥状
態であるモジュール、中空糸にグリセリン等の保湿剤が
付着した状態のモジュールに対し行なうことができる。
The irradiation of the electron beam is applied to a module filled with a filling liquid such as pure water or physiological saline, a module in which the hollow fiber is in a dry state, and a module in which a humectant such as glycerin is attached to the hollow fiber. You can do it.

【0015】本発明で用いられる電子線は、線量密度が
例えば5×102〜5×105kGy/hrのように高い
電子線が好ましく、出力では1KW以上がよい。従来の
γ線照射のように電子線に比べ線量密度が低く単位時間
当たりの放射線量が少ない場合(約1/1000)は、
十分な有機溶媒の分解作用が得られない。電子線のエネ
ルギーについては、物質透過性の観点からより高いエネ
ルギーの電子線がよいが、実際に使用できるエネルギー
には上限がある。好適には、5MeV〜10MeVのエ
ネルギーであれば、市販の電子線加速器がありそれらを
用いることができる。
The electron beam used in the present invention is preferably an electron beam having a high dose density, for example, 5 × 10 2 to 5 × 10 5 kGy / hr, and the output is preferably 1 KW or more. When the dose density is lower than the electron beam and the radiation dose per unit time is small (about 1/1000) as in the conventional γ-ray irradiation,
Sufficient organic solvent decomposition cannot be obtained. Regarding the energy of the electron beam, an electron beam having a higher energy is better from the viewpoint of material permeability, but there is an upper limit to the energy that can be actually used. Preferably, if the energy is 5 MeV to 10 MeV, a commercially available electron beam accelerator can be used.

【0016】本発明で照射する電子線の線量は、照射前
の残存している極性有機溶媒の濃度に依存するので特定
はできないが、好ましくは1KGy〜50KGy、より
好ましくは1KGy〜30KGyであり、具体的には、
例えば残存有機溶媒が100ppm程度であれば15K
Gy程度が必要であり、また、残存有機溶媒が50pp
m以下であれば5KGy以下の線量でも残存溶媒濃度を
50ppb以下にすることができる。したがって、照射
線量を低減するには、照射前に膜を組み込んだモジュー
ルをできるだけ洗浄して残存有機溶媒濃度をできるだけ
低減しておくことが望ましい。
The dose of the electron beam irradiated in the present invention cannot be specified because it depends on the concentration of the remaining polar organic solvent before irradiation, but is preferably 1 KGy to 50 KGy, more preferably 1 KGy to 30 KGy, In particular,
For example, if the residual organic solvent is about 100 ppm, 15K
Gy is required, and the remaining organic solvent is 50 pp.
m or less, the residual solvent concentration can be reduced to 50 ppb or less even at a dose of 5 KGy or less. Therefore, in order to reduce the irradiation dose, it is desirable that the module incorporating the film be cleaned as much as possible before irradiation to reduce the residual organic solvent concentration as much as possible.

【0017】本発明の膜を組み込んだモジュールとして
は、一般産業用、水処理用および血液処理用等で用いら
れているモジュール等があるが、特に、メディカル用途
において血漿交換療法や人工透析治療、さらには人工肝
臓、エンドトキシンフィルターおよびバイオリアクター
等の医療用途に用いられる透析器等の血液処理用モジュ
ールに好適である。
Modules incorporating the membrane of the present invention include modules used for general industry, water treatment, blood treatment, and the like. In particular, plasma exchange therapy, artificial dialysis treatment, Furthermore, it is suitable for blood processing modules such as dialysers used for medical applications such as artificial livers, endotoxin filters, and bioreactors.

【0018】以下、実施例によって本発明をさらに詳細
に説明するが、本発明はこれらに限定されない。
Hereinafter, the present invention will be described in more detail by way of examples, but the present invention is not limited thereto.

【0019】[0019]

【実施例】(実施例1)N,N−ジメチルアセトアミド
(以下DMAc)を有機溶媒としてポリスルホンを溶解
させたポリマー溶液から成形したポリスルホン系中空糸
(内径200μm、膜厚40μm)型人工透析器を洗浄
し、この透析器の充填液中のDMAcの濃度を120p
pmになるように調製した。次に、この透析器(モジュ
ール)に15KGyの電子線を照射したところ、充填液
中のDMAc濃度は、20ppb以下になった。吸収線
量の測定は、最大径を有するモジュール中心部に埋め込
んだCTAフィルム線量計を用いた(以下の実施例およ
び比較例も同様の方法で吸収線量の測定を行なった)。
(Example 1) A polysulfone-based hollow fiber (inner diameter 200 µm, film thickness 40 µm) type artificial dialyzer formed from a polymer solution in which polysulfone was dissolved using N, N-dimethylacetamide (hereinafter referred to as DMAc) as an organic solvent. After washing, the concentration of DMAc in the filling solution of the dialyzer was set to 120 p.
pm. Next, when this dialyzer (module) was irradiated with an electron beam of 15 KGy, the concentration of DMAc in the filling liquid became 20 ppb or less. For the measurement of the absorbed dose, a CTA film dosimeter embedded in the center of the module having the largest diameter was used (the absorbed dose was measured by the same method in the following Examples and Comparative Examples).

【0020】残存DMAcの測定は、GC−MS法(ガ
スクロマトグラフィーとマススペクトル分析を組み合わ
せた方法)によった。
The residual DMAc was measured by a GC-MS method (a method combining gas chromatography and mass spectrum analysis).

【0021】また、膜の強伸度特性評価(テンシロンに
よる引っ張り試験)により物理強度(破断強度18.5
gf)には変化が認められないことを確認した。また、
6ヶ月後再測定しても18.3gfと変化無かった。引
っ張り試験は初期試料長50mm、引っ張り速度50m
m/分、温度25℃、湿度50〜60%で行った。 (比較例1)実施例1と同じ、充填液中のジメチルアセ
トアミド(DMAc)の濃度を120ppmに調製した
ポリスルホン系中空糸型人工透析器を、500ml/m
inで15分間血液側ノズルから超純水で洗浄した。残
存ジメチルアセトアミドの濃度は1.2ppmであっ
た。 (比較例2)実施例1と同じ、充填液中のDMAcの濃
度を120ppmに調製したポリスルホン系中空糸型人
工透析器を、500ml/minで15分間血液側ノズ
ルから超純水で洗浄した後、さらに80℃の熱水で15
分間洗浄した。残存DMAcの濃度は120ppbであ
った。 (比較例3)実施例1と同じ、充填液中のDMAcの濃
度を120ppmに調製したポリスルホン系中空糸型人
工透析器を、500ml/minで15分間血液側ノズ
ルから超純水で洗浄した後、80℃の熱水で15分間洗
浄し、さらにγ線を25Gy照射した。残存DMAcの
濃度は112ppbであった。 (実施例2)比較例1の洗浄処理を施したポリスルホン
系中空糸型人工透析器に、さらに5KGyの電子線を照
射したところ、充填液中のDMAc濃度は、20ppb
以下になった。膜の強伸度特性評価(テンシロンによる
引っ張り試験)により物理強度(18.3gfから変化
なし)には変化が認められないことを確認した。また、
1ヶ月後に測定しても18.2gfと変化がなかった。 (実施例3)比較例2の洗浄処理を施したポリスルホン
系中空糸型人工透析器に、さらに5KGyの電子線を照
射したところ、充填液中のDMAc濃度は、20ppb
以下になった。膜の強伸度特性評価(テンシロンによる
引っ張り試験)により物理強度(18.5gfから1
8.3gf)には変化が認められないことを確認した。
また、1ヶ月後18.5gfと変化なかった。 (実施例4)比較例3の洗浄処理を施したポリスルホン
系中空糸型人工透析器に、さらに5KGyの電子線を照
射したところ、充填液中のDMAc濃度は、20ppb
以下になった。膜の強伸度特性評価(テンシロンによる
引っ張り試験)により物理強度(18.1gfから1
8.2gf)には変化が認められないことを確認した。
また、1ヶ月後にも18.2gfと変化なかった。 (実施例5)DMAcを有機溶媒としてポリスルホンを
溶解させたポリマー溶液から成形したポリスルホン系中
空糸(内径200μm、膜厚40μm)型人工透析器を
洗浄し、モジュールを乾燥させた。次にこの透析器(モ
ジュール)に15KGyの電子線を照射した。このモジ
ュール内に超純水を入れて80℃で24時間保存した後
の水中におけるDMAc濃度は、20ppb以下であっ
た。 (比較例4)実施例5と同様にして作成した乾燥モジュ
ールに25KGyのγ線をを照射した。このモジュール
内に超純水を入れて80℃で24時間保存した後の水中
におけるDMAc濃度は、1.5ppmであった。
The physical strength (rupture strength of 18.5) was determined by evaluating the strength and elongation characteristics of the film (tensile test using Tensilon).
It was confirmed that no change was observed in gf). Also,
Even after re-measurement after 6 months, there was no change of 18.3 gf. In the tensile test, the initial sample length was 50 mm and the tensile speed was 50 m
m / min, temperature 25 ° C., humidity 50-60%. (Comparative Example 1) A polysulfone-based hollow fiber type dialyzer in which the concentration of dimethylacetamide (DMAc) in the filling solution was adjusted to 120 ppm, which was the same as in Example 1, was used at 500 ml / m2.
The blood side nozzle was washed with ultrapure water for 15 minutes in. The concentration of residual dimethylacetamide was 1.2 ppm. (Comparative Example 2) A polysulfone-based hollow fiber artificial dialyzer in which the concentration of DMAc in the filling solution was adjusted to 120 ppm as in Example 1 was washed with ultrapure water from the blood side nozzle at 500 ml / min for 15 minutes. And with hot water at 80 ° C for 15
Washed for minutes. The concentration of residual DMAc was 120 ppb. (Comparative Example 3) After washing a polysulfone-based hollow fiber type artificial dialyzer in which the concentration of DMAc in the filling solution was adjusted to 120 ppm as in Example 1 with ultrapure water from the blood side nozzle at 500 ml / min for 15 minutes. After washing with hot water at 80 ° C. for 15 minutes, γ-rays were irradiated at 25 Gy. The concentration of residual DMAc was 112 ppb. (Example 2) When the polysulfone hollow fiber artificial dialyzer subjected to the washing treatment of Comparative Example 1 was further irradiated with an electron beam of 5 KGy, the DMAc concentration in the filling solution was 20 ppb.
It became the following. It was confirmed that no change was observed in the physical strength (no change from 18.3 gf) by evaluating the elongation characteristic of the film (tensile test with Tensilon). Also,
Even after one month measurement, there was no change of 18.2 gf. (Example 3) When the polysulfone-based hollow fiber type artificial dialyzer subjected to the washing treatment of Comparative Example 2 was further irradiated with an electron beam of 5 KGy, the DMAc concentration in the filling solution was 20 ppb.
It became the following. The physical strength (from 18.5 gf to 1) was determined by evaluating the elongation characteristic of the film (tensile test using Tensilon).
No change was observed in 8.3 gf).
One month later, there was no change to 18.5 gf. (Example 4) When the polysulfone-based hollow fiber type artificial dialyzer subjected to the washing treatment of Comparative Example 3 was further irradiated with an electron beam of 5 KGy, the concentration of DMAc in the filling solution was 20 ppb.
It became the following. The physical strength (from 18.1 gf to 1) was determined by evaluating the elongation characteristic of the film (tensile test using Tensilon).
No change was observed in 8.2 gf).
In addition, it was 18.2 gf even after one month. Example 5 A polysulfone-based hollow fiber (inner diameter: 200 μm, film thickness: 40 μm) type artificial dialyzer molded from a polymer solution in which polysulfone was dissolved using DMAc as an organic solvent was washed, and the module was dried. Next, this dialyzer (module) was irradiated with an electron beam of 15 KGy. After the ultrapure water was put in this module and stored at 80 ° C. for 24 hours, the DMAc concentration in the water was 20 ppb or less. (Comparative Example 4) A drying module prepared in the same manner as in Example 5 was irradiated with 25 KGy of γ-rays. After adding ultrapure water in this module and storing it at 80 ° C. for 24 hours, the DMAc concentration in the water was 1.5 ppm.

【0022】[0022]

【発明の効果】本発明によれば、特に高沸点の極性溶媒
を用いて製造した膜を組み込んだモジュールにおいても
残存有機溶媒量が少なく、残存する有機溶媒の影響で膜
劣化、モジュール劣化を起こすことがなく、水処理関係
および医療用途において使用時の安全性が確保されるモ
ジュールが得られる。
According to the present invention, the amount of the remaining organic solvent is small even in a module incorporating a film produced using a polar solvent having a high boiling point, and the film and the module are deteriorated by the influence of the remaining organic solvent. Thus, a module can be obtained in which safety during use in water treatment and medical applications is ensured.

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 膜を組み込んだモジュールにおいて、充
填液中の有機溶媒濃度もしくは充填液がない場合はモジ
ュール内に超純水を入れ80℃で24時間保存した後の
水中における有機溶媒濃度が、50ppb以下であるこ
とを特徴とする膜を組み込んだモジュール。
In a module incorporating a membrane, the concentration of the organic solvent in the filling liquid or the concentration of the organic solvent in water after ultrapure water is placed in the module and stored at 80 ° C. for 24 hours when there is no filling liquid, A module incorporating a membrane, which is 50 ppb or less.
【請求項2】 前記膜が分離膜または半透膜であること
を特徴とする請求項1記載の膜を組み込んだモジュー
ル。
2. The module according to claim 1, wherein the membrane is a separation membrane or a semipermeable membrane.
【請求項3】 前記膜がポリスルホン膜であり、有機溶
媒がN,N−ジメチルアセトアミドである請求項1また
は2記載の膜を組み込んだモジュール。
3. The module according to claim 1, wherein the membrane is a polysulfone membrane, and the organic solvent is N, N-dimethylacetamide.
【請求項4】 医療用途に用いられる請求項1〜3のい
ずれかに記載の膜を組み込んだモジュール。
4. A module incorporating the membrane according to claim 1, which is used for medical applications.
【請求項5】 膜を組み込んだモジュールに電子線を照
射して、残存する有機溶媒を分解せしめることを特徴と
する請求項1〜4のいずれかに記載の膜を組み込んだモ
ジュールの製造法。
5. The method for producing a module incorporating a film according to claim 1, wherein the module incorporating the film is irradiated with an electron beam to decompose the remaining organic solvent.
【請求項6】 前記電子線の照射量が1〜50KGyで
ある請求項5記載の膜を組み込んだモジュールの製造
法。
6. The method according to claim 5, wherein the irradiation amount of the electron beam is 1 to 50 KGy.
JP33612699A 1998-11-27 1999-11-26 Module incorporating a membrane and manufacturing method thereof Expired - Fee Related JP4622015B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP33612699A JP4622015B2 (en) 1998-11-27 1999-11-26 Module incorporating a membrane and manufacturing method thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP33781698 1998-11-27
JP10-337816 1998-11-27
JP33612699A JP4622015B2 (en) 1998-11-27 1999-11-26 Module incorporating a membrane and manufacturing method thereof

Publications (2)

Publication Number Publication Date
JP2000218140A true JP2000218140A (en) 2000-08-08
JP4622015B2 JP4622015B2 (en) 2011-02-02

Family

ID=26575371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP33612699A Expired - Fee Related JP4622015B2 (en) 1998-11-27 1999-11-26 Module incorporating a membrane and manufacturing method thereof

Country Status (1)

Country Link
JP (1) JP4622015B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100813889B1 (en) * 2002-08-20 2008-03-18 주식회사 코오롱 A process of preparing for polysulfone-based hollow fiber membranes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01210094A (en) * 1988-02-17 1989-08-23 Taisei Corp Ultra pure service water treatment and its facility
JPH02164490A (en) * 1988-12-19 1990-06-25 Japan Atom Energy Res Inst Water treatment method and apparatus
JP3623007B2 (en) * 1995-04-05 2005-02-23 テルモ株式会社 Artificial organ and sterilization method thereof
JPH0952015A (en) * 1995-08-18 1997-02-25 Shinko Pantec Co Ltd Solvent treatment apparatus and method therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100813889B1 (en) * 2002-08-20 2008-03-18 주식회사 코오롱 A process of preparing for polysulfone-based hollow fiber membranes

Also Published As

Publication number Publication date
JP4622015B2 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
JP3772909B1 (en) Blood purifier
JP4848278B2 (en) Highly permeable hollow fiber membrane blood purifier and method for producing the same
JP4453248B2 (en) Method for producing hollow fiber membrane and hollow fiber membrane module
JPH089668B2 (en) Hydrophilized film and method for producing the same
EP2962712B1 (en) Hemopurifier package and process for producing the same
US4148606A (en) Sterilization of dialyzer
DK171139B1 (en) Process for producing a polymer article of reduced thrombogenicity
EP1410839B1 (en) Hollow fiber membrane for purifying blood
EP1813298B1 (en) Blood purification device and blood purification device package
US6010475A (en) Apparatus for the treatment of blood by extracorporeal circulation and process of manufacture
JPS6246190B2 (en)
JP3928910B2 (en) Polysulfone blood treatment module
JP2006291193A (en) Reformed substrate and manufacturing method thereof
JP2004305840A (en) Method for preserving hollow fiber membrane
JP2010233999A (en) Blood purifier
JP3076080B2 (en) Processing method for permselective membrane
JP2000218140A (en) Module incorporated with membrane and its production
GB1567133A (en) Sterilization of membranes
JPS63100998A (en) Production of ultrapure water
JP2000135421A (en) Polysulfone-base blood purifying membrane
JP3193262B2 (en) Blood processing device manufacturing method and blood processing device
JPS63111878A (en) Sterilization of semipermeable membrane module
JP4678063B2 (en) Hollow fiber membrane module
JP2779257B2 (en) Blood processing equipment sterilization method
JP4738728B2 (en) Hollow fiber blood processor and sterilization packaging method thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20081009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081021

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101005

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101018

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131112

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees